Exhibit 99.1 Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights • Actively enrolling subjects in ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease • Dosed the first subject in a Phase 1 study to support subcutaneous administration of sabirnetug in July 2024 with topline results anticipated in the first quarter of 2025 • Cash, cash equivalents and marketable securities of $281.4 million as of Jun. 30, 2024, ...

Jonathan Kitchen Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a clinical-stage biopharmaceutical company that develops innovative treatments for AD, specifically targeting toxic soluble AβOs that accumulate in the brain, producing synapse deterioration, tau hyper-phosphorylation, and inflammation. These factors contribute to neuronal death, leading to cognitive and functional impairments. ABOS’s leading drug candidate, Sabirnetug, is a monoclonal antibody designed to neutralize AβOs to preserve neurona ...

NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) in the brain for the treatment of Alzheimer's disease (AD), today announced that the first subject has been dosed with a subcutaneous formulation of sabirnetug (ACU193) in a Phase 1 pharmacokinetic (PK) comparison study. The study plans to compare the PK between subcutaneous and intravenous ad ...

NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193). The research highlights the experiences of patients in the clinical trial to inform development of future trials, biomarker data to support sabirnetug's ...

NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193). The research highlights the experiences of patients in the clinical trial to inform development of future trials, biomarker data to support sabirnetug’ ...

NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the Company will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC®) 2024 taking place in Philadelphia ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________ FORM 10-Q ___________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40551 ___________________________ Acum ...

Financial Data and Key Metrics Changes - As of March 31, 2024, the company had approximately $297 million in cash and marketable securities, with an expected cash runway lasting into the first half of 2027 [10] - R&D expenses for Q1 2024 were $12.4 million, an increase attributed to spending for the ALTITUDE-AD trial [11] - G&A expenses were $5.3 million for the quarter, reflecting an increase due to higher headcount, leading to a loss from operations of $17.8 million [11] Business Line Data and Key Metrics Changes - The ALTITUDE-AD Phase II study has commenced, with the first patient dosed, aiming to evaluate the efficacy and safety of sabirnetug in approximately 540 participants [7][8] - The company is also on track to initiate a Phase I study for a subcutaneous formulation of sabirnetug in mid-2024, which is expected to provide additional flexibility for patients [9] Market Data and Key Metrics Changes - The company is encouraged by the early engagement and interest from trial sites for the ALTITUDE study, which may be positively influenced by the Phase I INTERCEPT results [7][27] Company Strategy and Development Direction - The company aims to establish sabirnetug as a best-in-class treatment for early Alzheimer's patients, focusing on advancing clinical development efficiently [9] - A collaboration agreement with Lonza for manufacturing sabirnetug has been established, leveraging Lonza's expertise for clinical development and commercialization [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the ALTITUDE study's early progress and the potential for sabirnetug to provide significant value to patients and shareholders [9][27] - The company is closely monitoring the implications of competing products like lecanemab and donanemab on enrollment expectations for the ALTITUDE study [26][27] Other Important Information - The company is committed to delivering updates throughout the year as it advances the sabirnetug program [11] Q&A Session Summary Question: Is R&D about stable now, or are we expecting it to go up significantly? - R&D is expected to trend up for the next couple of quarters before flattening out and then decreasing [12][13] Question: Do you have a sense of what you're looking for in the subcutaneous formulation? - The focus is on getting the healthy volunteer study up and evaluating pharmacokinetics, with considerable optionality for future steps [14][15] Question: Can you ultimately get to a plaque-busting dose with the subcutaneous formulation? - The goal remains consistent with the INTERCEPT study, focusing on oligomer target engagement and some plaque reduction [18][19] Question: What are the implications of the upcoming donanemab AdComm? - The AdComm will focus on treatment duration and stratification concerns, which may have implications for market development [20] Question: Can the subcutaneous formulation be used within ALTITUDE if the healthy volunteer study goes well? - While theoretically possible, it would be logistically challenging to insert the subcutaneous formulation into the already designed ALTITUDE study [28][29]

Exhibit 99.1 Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights • Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024 • Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid- 2024 • Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activi ...

Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, ...